ライフサイエンスコーパス: biliary obstruction

1 orrectable complications (eg, pseudocysts or biliary obstruction).

2 e quality of life in patients with malignant biliary obstruction.

3 post-ERC infectious events in patients with biliary obstruction.

4 holedocholithiasis and alternative causes of biliary obstruction.

5 2015, including 823 patients with malignant biliary obstruction.

6 isk patients, including those with malignant biliary obstruction.

7 morbidity because the tumor typically causes biliary obstruction.

8 ing the ERC procedure in tumor patients with biliary obstruction.

9 iliary stent for the palliation of malignant biliary obstruction.

10 nt with unresectable disease and features of biliary obstruction.

11 d biliary bypass in the setting of malignant biliary obstruction.

12 is the modality of choice for palliation of biliary obstruction.

13 and underused approach to managing bowel and biliary obstruction.

14 ployment of metal stents for malignant hilar biliary obstruction.

15 particularly in subjects without evidence of biliary obstruction.

16 for the treatment of patients with malignant biliary obstruction.

17 BD as a rescue strategy in case of malignant biliary obstruction.

18 an, and use of metal stents in patients with biliary obstruction.

19 -expandable metal stents for malignant hilar biliary obstruction.

20 n age 74.66 [56-89] years) with unresectable biliary obstruction.

21 ment of patients with unresectable malignant biliary obstruction.

22 among the groups of patients with malignant biliary obstruction (1.8%), history of bile duct injury

23 Of the 16 patients with symptoms of biliary obstruction, 13 had resolution of their symptoms

24 mostatic therapy (2), enteral access (6), or biliary obstruction (2).

25 Thirteen (42%) patients had intrahepatic biliary obstruction; 27 (87%) patients had involvement o

26 ers, but were rarely present in extrahepatic biliary obstruction, alcoholic fibrosis, or normal liver

27 Patients with malignant biliary obstruction, altered GI anatomy, and choledochol

28 l for patients with suspected cholangitis or biliary obstruction, although the concomitance of these

29 s-sectional imaging can provide evidence for biliary obstruction and a malignancy arising from the bi

30 3%, with two patients experiencing recurrent biliary obstruction and cholangitis.

31 Biliary obstruction and cholestasis can cause hepatocell

32 ctive study included patients with malignant biliary obstruction and hyperbilirubinemia who underwent

33 with the reassortants and were monitored for biliary obstruction and mortality.

34 system appears to be effective at relieving biliary obstruction and preventing re-intervention withi

35 accounted for benign and malignant causes of biliary obstruction and procedural complications.

36 ct as endotherapy for unresectable malignant biliary obstruction and to determine factors affecting t

37 accurate in picking a mass as the cause for biliary obstruction and was able to differentiate a beni

38 of lymphocyte subtypes on the development of biliary obstruction, and coculture and cell transfer exp

39 cobiliary disease, the presence and level of biliary obstruction, and obstruction due to bile duct ca

40 gallbladder disease, high-grade and partial biliary obstruction, and the postcholecystectomy pain sy

41 may be accompanied by features of transient biliary obstruction, and those of pancreatic SO dysfunct

42 Patients with biliary obstruction are at high risk to develop septic c

43 rom all patients treated for malignant hilar biliary obstruction at our institution between May 2019

44 patients with potentially resectable PHC and biliary obstruction between preoperative endoscopic or p

45 n the setting of liver dysfunction caused by biliary obstruction can be associated with increased mor

46 These adverse effects of biliary obstruction can be inhibited by administration o

47 Relief from biliary obstruction can be provided with temporary plast

48 d with biliary stent placement for malignant biliary obstruction can be safe and feasible, and effect

49 Twenty-two patients with unresectable biliary obstruction caused by cholangiocarcinoma (n = 11

50 uction, Bismuth- Corlette type IV stricture, biliary obstruction caused by gallbladder cancer and whe

51 infections; 10% had graft ischemia; 15% had biliary obstruction/cholangitis; 3% had a combination of

52 e literature addressed therapy for malignant biliary obstruction, choledocholithiasis, and biliary co

53 n BEC proliferation at 15 and 24 hours after biliary obstruction compared with adenovirus control.

54 Patients with extrahepatic biliary obstruction do not necessarily require immediate

55 et, prospective study included patients with biliary obstruction due to a malignant neoplasm treated

56 ing chronic active hepatitis C, extrahepatic biliary obstruction (EBO), and normal liver, using nonis

57 Six patients had biliary obstruction; five were treated percutaneously be

58 Male Sprague-Dawley rats received reversible biliary obstruction for 7 days, and the rat PMN-specific

59 cond group of papers evaluated patients with biliary obstructions from proximal biliary neoplasms.

60 if a patient has the tetrad of pancreatitis, biliary obstruction, gastric outlet obstruction and rapi

61 er, he was found to have acute pancreatitis, biliary obstruction, gastric outlet obstruction and rapi

62 CSEMS), intended for palliation of malignant biliary obstruction, have been used to treat benign bili

63 al analysis yielded the absence of recurrent biliary obstruction in 99.0% of patients at 1 month (n =

64 Activation of hepatic T-lymphocytes driving biliary obstruction in BA is regulated by mDCs by way of

65 f iNKT cells in liver injury associated with biliary obstruction in mice with ligations of the common

66 rning the outcome of patients with malignant biliary obstruction in relationship to microbial isolate

67 by ERCP may provide improved palliation from biliary obstruction in the future.

68 ne the role of B cells in the development of biliary obstruction in the Rhesus rotavirus (RRV)-induce

69 icient Ig-alpha(-/-) mice are protected from biliary obstruction in the RRV-induced mouse model of BA

70 f Tregs in Ig-alpha(-/-) mice did not induce biliary obstruction, indicating that the expanded Tregs

71 at endoscopic biliary drainage for malignant biliary obstruction is a first-line intervention.

72 tine preoperative decompression of malignant biliary obstruction is associated with a higher frequenc

73 Malignant hilar biliary obstruction is associated with a poor prognosis,

74 etal stents for unresectable malignant hilar biliary obstruction is feasible and safe, with high succ

75 Management of biliary obstruction is obligatory in perihilar cholangio

76 Acute biliary obstruction leads to periductal myofibroblasts a

77 , younger patients suspected of having acute biliary obstruction likely benefit from MR cholangiopanc

78 This review focuses on treatment of biliary obstruction, malignant gastric outlet obstructio

79 s short- and long-term outcomes of malignant biliary obstruction (MBO) treatment by percutaneous tran

80 Liver Volume, Hyperbilirubinemia, Malignant Biliary Obstruction, Objective Measurement (C) RSNA, 202

81 rol group contained 13 PSC patients, 16 with biliary obstruction of varying etiologies (including ben

82 For patients with cancer and biliary obstruction, preoperative biliary stenting appea

83 sfunction in patients with some evidence for biliary obstruction (previously SOD type II, now called

84 ow-risk patients and patients with malignant biliary obstruction, rectal indomethacin was associated

85 luding gastrointestinal luminal obstruction; biliary obstruction; recurrent acute pancreatitis; fistu

86 Freedom from symptomatic recurrent biliary obstruction requiring re-intervention was achiev

87 In addition, biliary obstruction resulted in increased expression of

88 Biliary obstruction results in a well-characterized chol

89 fter evaluation for radiological evidence of biliary obstruction, the animals were sacrificed and por

90 In the absence of biliary obstruction, the average cost per correct diagno

91 endpoints included complications, recurrent biliary obstruction, time to recurrent obstruction, rein

92 nt results of all patients with unresectable biliary obstruction treated with EUS-guided hepaticogast

93 The location of the biliary obstruction was classified as Bismuth type III (

94 lantation and who presented with symptoms of biliary obstruction were examined.

95 17 to March 2021, 18 patients with malignant biliary obstruction who had undergone percutaneous EB-RF

96 tological picture indicative of extrahepatic biliary obstruction with negligible inflammation/necrosi

97 o be used for palliation of malignant distal biliary obstruction with superior patency to plastic ste

98 n outcome measure was freedom from recurrent biliary obstruction (within the stent) requiring re-inte